1
Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Lynch Christopher, Mills Sander G, Neway William Edward Iii, Toth Leslie: 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists. Merck & Co, Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Lynch Christopher, Mills Sander G, Neway William Edward Iii, Toth Leslie, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 2, 2004: WO/2004/103279 (94 worldwide citation)

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of ...


2
Dorn Conrad P, Hale Jeffrey J, Maccoss Malcolm, Mills Sander G, Ladduwahetty Tamara, Shah Shrenik K: Morpholine and thiomorpholine tachykinin receptor antagonists.. Merck & Co, January 5, 1994: EP0577394-A1 (78 worldwide citation)

Substituted heterocycles of the general structural formula: are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.


3
Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Huo Pei, Legiec Irene E, Toth Leslie, Vachal Petr, Yan Lin: (edg) Receptor agonists. Merck & Co, Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Huo Pei, Legiec Irene E, Toth Leslie, Vachal Petr, Yan Lin, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 30, 2005: WO/2005/058848 (69 worldwide citation)

The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocyt ...


4
Doherty George A, Hale Jeffrey J, Legiec Irene E, Lynch Christopher L, Toth Leslie M: 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists. Merck & Co, Doherty George A, Hale Jeffrey J, Legiec Irene E, Lynch Christopher L, Toth Leslie M, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, April 14, 2005: WO/2005/032465 (54 worldwide citation)

The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods o ...


5

6
Fletcher Joan M, Hale Jeffrey J, Miao Shouwu, Vachal Petr: Spiroindalones. Merck & Co, Fletcher Joan M, Hale Jeffrey J, Miao Shouwu, Vachal Petr, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, November 27, 2008: WO/2008/144266 (20 worldwide citation)

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.


7

8
Doherty George A, Hale Jeffrey J, Mills Sander G: (amino)Indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles. Merck & Co, Doherty George A, Hale Jeffrey J, Mills Sander G, sMERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 15, 2004: WO/2004/058149 (16 worldwide citation)

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions an ...


9

10
Debenham John S, Hale Jeffrey J, Huo Pei, Madsen Duggan Christina B, Walsh Thomas F, Yan Lin: Substituted pyrano[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators. Merck & Co, Debenham John S, Hale Jeffrey J, Huo Pei, Madsen Duggan Christina B, Walsh Thomas F, Yan Lin, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, August 7, 2008: WO/2008/094473 (6 worldwide citation)

Novel compounds of the structural Formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs ...